This project is designed to test a novel hypothesis that cancer cells communicate with the host via C5a/C5aR- induced systemic SK1/S1P, which then promotes tumor metastasis, and that inhibition of systemic S1P/C5aR signaling suppresses metastasis. To test this hypothesis, three Specific Aims are proposed:
Aim 1 is designed to define the roles and mechanisms of cancer cell-induced vascular endothelial cell complement signaling and systemic SK1/S1P in the regulation of tumor metastasis.
Aim 2 is designed to determine the down-stream mechanisms by which cancer cell-induced systemic SK-1/S1P promotes tumor metastasis. In this Aim, our main goal is to test our hypothesis that cancer cell-induced systemic SK1/S1P inhibits the expression of a master suppressor of metastasis (BRMS1) via S1PR2 signaling in cancer cells, inducing tumor metastasis.
Aim 3 is designed to determine the therapeutic efficacy of targeting systemic S1P and/or C5a signaling for the attenuation of tumor metastasis. In this Aim, our main goal is to test a novel hypothesis that inhibition of systemic C5aR/SK1/S1P signaling will inhibit tumor metastasis via activation of tumor BRMS1. These studies will help uncover how cancer cells communicate with the host via SK1/S1P and complement signaling to regulate tumor metastasis, leading to the development of novel therapeutic strategies for the inhibition of tumor growth or metastasis. In this project, we will also determine if the elevation of systemic S1P/C5a in patients with advanced solid tumors will provide novel serum markers for monitoring response to therapy and/or early detection of progression to metastasis.
Studies proposed in this project will help uncover how cancer cells communicate with the host via systemic sphingolipid and complement signaling to regulate tumor metastasis, leading to the development of novel therapeutic strategies for the inhibition of metastasis.
|Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800|
|Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara et al. (2018) Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res :|
|Schrecengost, Randy S; Green, Cecelia L; Zhuang, Yan et al. (2018) In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. J Pharmacol Exp Ther 365:107-116|
|Ogretmen, Besim (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 18:33-50|
|Helke, Kristi; Angel, Peggi; Lu, Ping et al. (2018) Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Sci Rep 8:1627|
|Chatterjee, Shilpak; Daenthanasanmak, Anusara; Chakraborty, Paramita et al. (2018) CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab 27:85-100.e8|
|Britten, Carolyn D; Garrett-Mayer, Elizabeth; Chin, Steven H et al. (2017) A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 23:4642-4650|
|Lv, Zongyang; Rickman, Kimberly A; Yuan, Lingmin et al. (2017) S. pombe Uba1-Ubc15 Structure Reveals a Novel Regulatory Mechanism of Ubiquitin E2 Activity. Mol Cell 65:699-714.e6|
|Thomas, Raquela J; Oleinik, Natalia; Panneer Selvam, Shanmugam et al. (2017) HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy. EMBO Mol Med 9:1030-1051|
|Scheffel, Matthew J; Helke, Kristi; Lu, Ping et al. (2017) Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. Sci Rep 7:15552|
Showing the most recent 10 out of 13 publications